Silverarc Capital Management’s Trevi Therapeutics TRVI Stock Holding History

Silverarc Capital Management’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.1M	Sell	511,127 -30,113	-6%	-$337K	0.62%	38
2025 Q4	$6.78M	Sell	541,240 -47,549	-8%	-$550K	0.94%	29
2025 Q3	$5.39M	Buy	588,789 +49,202	+9%	+$369K	0.73%	36
2025 Q2	$2.95M	Buy	539,587 +9,587	+2%	+$59.6K	0.54%	42
2025 Q1	$3.33M	Sell	530,000 -204,234	-28%	-$974K	0.68%	40
2024 Q4	$3.03M	Buy	734,234 +251,659	+52%	+$806K	0.66%	40
2024 Q3	$1.61M	Sell	482,575 -361,660	-43%	-$1.08M	0.36%	51
2024 Q2	$2.52M	Hold	844,235	–	–	0.59%	45
2024 Q1	$2.91M	Sell	844,235 -19,648	-2%	-$43.8K	0.81%	37
2023 Q4	$1.16M	Sell	863,883 -63,532	-7%	-$96.2K	0.34%	57
2023 Q3	$2.02M	Buy	927,415 +41,491	+5%	+$93.7K	0.61%	45
2023 Q2	$2.12M	Hold	885,924	–	–	0.66%	44
2023 Q1	$1.64M	Buy	885,924 +118,293	+15%	+$268K	0.68%	48
2022 Q4	$1.48M	Sell	767,631 -171,634	-18%	-$338K	0.42%	60
2022 Q3	$1.45M	Buy	+939,265	New	+$3.08M	0.49%	55

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Silverarc Capital Management's TRVI Position: Q1 2026 in Review

Silverarc Capital Management reduced its Trevi Therapeutics (TRVI) stake by 5.6% in Q1 2026, selling an estimated $337K and leaving 511,127 shares worth $6.1M. The position accounts for 0.62% of the portfolio, ranked #38.

Silverarc Capital Management first reported a position in TRVI in Q3 2022 and has held it in 15 quarters since. The position peaked at $6.78M in Q4 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

Silverarc Capital Management held 511,127 shares of Trevi Therapeutics worth $6.1M as of Q1 2026.
Silverarc Capital Management sold 30,113 Trevi Therapeutics shares in Q1 2026, an estimated $337K.
Trevi Therapeutics made up 0.62% of Silverarc Capital Management's portfolio in Q1 2026, its #38 holding.
Silverarc Capital Management first reported a position in Trevi Therapeutics in Q3 2022 and has held it in 15 quarters since.
Silverarc Capital Management's Trevi Therapeutics position peaked at $6.78M in Q4 2025.
198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.